Greenleaf Trust’s Alkermes ALKS Stock Holding History

Greenleaf Trust’s Portfolio ALKS Stock Details ALKS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$306K	Buy	5,845 +53	+0.9%	+$2.07K	﹤0.01%	686
2026 Q1	$205K	Buy	+5,792	New	+$180K	﹤0.01%	777

Other funds holding ALKS

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Greenleaf Trust's ALKS Position: Q2 2026 in Review

Greenleaf Trust increased its Alkermes (ALKS) stake by 0.92% in Q2 2026, buying an estimated $2.07K and bringing the position to 5,845 shares worth $306K. The position accounts for ﹤0.01% of the portfolio, ranked #686.

Greenleaf Trust first reported a position in ALKS in Q1 2026 and has held it in 2 quarters since. 425 funds tracked by Wall St. Rank hold ALKS as of Q2 2026.

Greenleaf Trust held 5,845 shares of Alkermes worth $306K as of Q2 2026.
Greenleaf Trust bought 53 Alkermes shares in Q2 2026, an estimated $2.07K.
Alkermes made up ﹤0.01% of Greenleaf Trust's portfolio in Q2 2026, its #686 holding.
Greenleaf Trust first reported a position in Alkermes in Q1 2026 and has held it in 2 quarters since.
425 funds tracked by Wall St. Rank held Alkermes as of Q2 2026.

Based on Greenleaf Trust's 13F filing for Q2 2026, filed 21 Jul 2026.